Trials / Completed
CompletedNCT03352323
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Padagis LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
the study will measure the decrease in redness on the face of rosacea subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxymetazoline | RLD |
Timeline
- Start date
- 2017-10-18
- Primary completion
- 2017-12-06
- Completion
- 2018-03-30
- First posted
- 2017-11-24
- Last updated
- 2021-11-08
- Results posted
- 2021-01-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03352323. Inclusion in this directory is not an endorsement.